Based on the role of KRAS in NSCLC, novel agents have been added to the therapeutic arsenal against NSCLC and are currently used in clinical practice, such as the oral KRAS p.G12C inhibitors, small molecule drugs that were specifically designed for this mutation [29]. Here, KRAS is linked to non-small cell lung carcinoma.